Schwarz K Q, Bezante G P, Becher H, Schimpfky C, Vorwerk D, Bogdahn U, Schlief R
Cardiology Unit, University of Rochester Medical Center, NY 14642.
Radiol Med. 1994 May;87(5 Suppl 1):3-14.
SH U 508 A (Levovist) as a blood pool enhancer to investigate multiple vascular regions with Doppler ultrasonography. Thirty patients with sub-optimal cardiac or peripheral vascular Doppler exams received 75 intravenous contrast bolus injections in all to investigate the intensity and the duration of Doppler signal enhancement after the i.v. administration of an echo contrast agent - i.e., SH U 508 A (Levovist) by Schering AG, Berlin, Germany. All cases exhibited Doppler enhancement and the investigator's "diagnostic confidence" increased from 35% (precontrast) to 91% (post-contrast) (p < 0.05). Audio Doppler intensity was measured quantitatively and more than 16 dB enhancement was demonstrated in all the vascular regions under investigation (p < 0.05). Enhancement lasted more than 60 seconds in the peripheral vessels and 120 seconds in the heart vessels. No clinically relevant adverse reactions were ever observed. To conclude, i.v., -administered SH U 508 A (Levovist) is a valuable means of increasing cardiac, femoral arterial and transcranial (cerebral arterial) Doppler signal intensity. Enhancement is durable and improves the clinical diagnostic confidence in the patients with suboptimal Doppler findings.
舒 508A（利声显）作为血池增强剂，用于通过多普勒超声检查多个血管区域。30 例心脏或外周血管多普勒检查结果欠佳的患者共接受了 75 次静脉造影剂团注注射，以研究静脉注射回声造影剂（即德国柏林先灵公司生产的舒 508A（利声显））后多普勒信号增强的强度和持续时间。所有病例均显示多普勒信号增强，研究者的“诊断信心”从造影前的 35%提高到造影后的 91%（p < 0.05）。对音频多普勒强度进行了定量测量，在所有受检血管区域均显示增强超过 16 dB（p < 0.05）。外周血管的增强持续超过 60 秒，心脏血管的增强持续 120 秒。从未观察到临床相关的不良反应。总之，静脉注射舒 508A（利声显）是增加心脏、股动脉和经颅（脑动脉）多普勒信号强度的一种有价值的方法。增强效果持久，提高了多普勒检查结果欠佳患者的临床诊断信心。
